Literature DB >> 11342685

A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease.

M T Hu1, S J White, A H Herlihy, K R Chaudhuri, J V Hajnal, D J Brooks.   

Abstract

OBJECTIVE: To quantify structural changes in the substantia nigra of patients with PD with inversion recovery MRI and to compare these with striatal dopaminergic function measured with (18)F-dopa PET.
METHODS: The authors studied 10 patients with PD and eight age-matched control subjects with a combination of MR sequences previously reported to be sensitive to nigral cell loss. Striatal regions of interest were defined on T1-weighted MRI coregistered to (18)F-dopa PET in all subjects.
RESULTS: Discriminant function analysis of the quantified MR nigral signal correctly classified 83% of the combined PD patient/control group; three of 10 PD cases were incorrectly classified as "normal" (Wilks' lambda = 0.724, p > 0.05). Discriminant function analysis correctly classified 100% of PD patients and control subjects with (18)F-dopa PET based on mean caudate and putamen K(i) values (Wilks' lambda = 0.065, p < 0.001). Correlations between mean putamen K(i) and rostral and caudal nigral MR signal changes and mean caudate K(i) and caudal nigral MR signal changes were found (r = -0.76, -0.69, -0.80, p < 0.05).
CONCLUSION: (18)F-dopa PET is more reliable than inversion recovery MRI in discriminating patients with moderately severe PD from normal subjects. However, the structural changes detected within the substantia nigra of patients with PD found using inversion recovery MRI correlate with measures of striatal dopaminergic function using (18)F-dopa PET.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342685     DOI: 10.1212/wnl.56.9.1195

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

3.  Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.

Authors:  Y Murakami; S Kakeda; K Watanabe; I Ueda; A Ogasawara; J Moriya; S Ide; K Futatsuya; T Sato; K Okada; T Uozumi; S Tsuji; T Liu; Y Wang; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

Review 4.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

5.  Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?

Authors:  Julie A Robichaud; Kerstin D Pfann; Sue Leurgans; David E Vaillancourt; Cynthia L Comella; Daniel M Corcos
Journal:  Clin Neurophysiol       Date:  2008-12-11       Impact factor: 3.708

6.  High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

Authors:  D E Vaillancourt; M B Spraker; J Prodoehl; I Abraham; D M Corcos; X J Zhou; C L Comella; D M Little
Journal:  Neurology       Date:  2009-01-07       Impact factor: 9.910

7.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

8.  Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis.

Authors:  Sarah Jesse; Jan Kassubek; Hans-Peter Müller; Albert C Ludolph; Alexander Unrath
Journal:  BMC Neurol       Date:  2012-12-29       Impact factor: 2.474

9.  Mild cognitive impairment in Parkinson's disease: the challenge and the promise.

Authors:  Hubert H Fernandez; Gregory P Crucian; Michael S Okun; Catherine C Price; Dawn Bowers
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

10.  Ketotherapeutics for neurodegenerative diseases.

Authors:  Nicholas G Norwitz; Javier Gilbert Jaramillo; Kieran Clarke; Adrian Soto
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.